Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

BioGaia

BioGaia

BioGaia develops, markets and sells probiotic products. Probiotics are useful bacteria that have documented positive health effects in the body. The applications for BioGaia products are mainly in gastrointestinal, oral and immune health and the products are available in a variety of different types of bottles. Sales are mainly through distribution partners in pharmacies worldwide. The company has two business areas: Pediatrics and Adult Health.

We note a number of risks factors for BioGaia, including market risk, partnership risk, competition, legal and regulatory risk, product development risk and currency and macroeconomic risk. From a short-term perspective there is a risk of destocking effect in some markets.

Equity research

Read earlier research

Media

BioGaia - Interview with CEO Isabelle Ducellier
BioGaia - Company presentation with CEO Isabelle Ducellier (in Swedish)

Main shareholders - BioGaia

Main shareholders Share capital % Voting shares % Verified
Peter Rotschild & Jan Annwall 7.2 % 33.0 %
Swedbank Robur Fonder 9.4 % 6.8 %
Fjärde AP-fonden 7.5 % 5.4 %
Old Mutual 7.3 % 5.3 %
Sebastian Jahreskog 6.9 % 5.0 %
David Dangoor 3.0 % 2.2 %
Juno Investment Partners 2.4 % 1.7 %
Norges Bank 1.9 % 1.3 %
Tredje AP-fonden 1.8 % 1.3 %
Didrik Hamilton 1.4 % 1.0 %